Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Risk Factors, Etiology and Predictable Outcomes With Risk Stratification Scores in Acute Heart Failure Patients

NCT07785531 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-08
Last updated
2026-08-25

Condition(s) studied

Acute Heart Failure (AHF)

Investigational drug(s) / intervention(s)

EchoEcgCreatinineTroponin

Echo: Echo for clinical assessment

Ecg: Twelve leads ECG to detect any ischemic changes

Creatinine: To detect renal function test

Troponin: Ischemic changes

Study summary

Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age more than 18yrs * Clinical diagnosis of acute heart failure according to current ESC guideline criteria. Exclusion Criteria: * Age below than 18 * Refusal to participate.

Primary outcome measure(s)

  • Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital. — Follow up patients for 30 days
    To externally validate the HEARTRISK6 score and evaluate its predictive performance for short-term adverse outcomes in patients with acute heart failure. History of moderate/severe valvular heart disease\_Yes. 1 Heart rate \>100 to ≤120 bpm. 2 \>120 bpm. 3 Non-invasive ventilation (NIV)BiPAP/NIV within first hour 2 Creatinine \>150 to ≤300 µmol/L 2 \>300 µmol/L. 3 Troponin \>3-5 × upper reference limit (URL) 1 \>5 × URL. 2 Failed reassessment / 3-minute walk test ifFailed1 comp0 High score means worse

Trial sites (1)

FacilityCityRegionStatus
AssiutU Asyut Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07785531 on ClinicalTrials.gov ↗ ← All trials in Egypt